ZATA Obtained Commercialization Right for the Antithrombotic Drug Candidate GLS409

On November 2th, 2017 ZATA Pharmaceuticals obtained exclusive licensing and commercialization right for the antithrombotic drug candidate GLS409 from GLSynthesis, Inc., Worcester, MA.

GLS409 is a very potent platelet aggregation inhibitor, with a unique new mechanism of action, targeting simultaneously both platelets’ ADP receptors, P2Y1 and P2Y12. This drug candidate have been developed by GLSynthesis in collaboration with the Center for Platelet Research Studies at Children’s Hospital and Harvard Medical School and the Cardiovascular Research Institute at Wayne State University School of Medicine.

The drug candidate showed highly potent antithrombotic effect in the canine model of acute coronary syndrome without increase of animals bleeding time. Because of its unique mechanism of action it is expected, unlike Plavix and other P2Y12 receptor targeting drugs, to have a minimal interpatient variability of the antiplatelet effect.

GLS409 is intended as an IV treatment during and immediately after Percutaneous Coronary Intervention (PCI) procedure in a catheterization lab, or as a first-in-line treatment for patients presenting with acute coronary syndrome symptoms. It is also intended as treatment for patients in need of antiplatelet therapy, who are in risk of bleeding or may need surgical intervention.

Presently ZATA Pharmaceutical is actively seeking licencing or investment opportunity that will enable the initiation of human clinical testing of GLS409.

March 27th, 2018

On March 27^th Dr. David Tabatadze will deliver a presentation at the Oligonucleotide Discovery and Delivery conference in Cambridge, MA. Link: http://www.optcongress.com/?utm_source=AdRoll&utm_medium=Banner&utm_campaign=OPS%202018

September 25-29 2017

Dr. David Tabatadze, President and CEO of ZATA presented ZATA’s new generation oligonucleotides at the “Discovery on Target” meeting in Boston, MA on September 25-29, 2017 (http://www.discoveryontarget.com/Oligonucleotide-Therapeutics). The meeting addressed advances in genomics, gene editing, oligonucleotide synthesis, delivery and manufacturing.

June 25-30, 2017

   Dr. Ivan Ianachkov, VP of Medicinal Chemistry, has presented for the first time ZATA’s Oligonucleotide technology to the professional community at the Gordon Scientific Conference in Newport, MA Nucleosides, Nucleotides and Oligonucleotides (https://www.grc.org/programs.aspx?id=12058). The scientific community received ZATA’s technology with high interest and enthusiasm.

 

May 2017

  ZATA relocated to MBI’s new Gateway Park facility in Worcester, MA. The facility is located within the WPI Life Sciences & Bioengineering Center (LSBC) at Gateway Park and possess unique set-ups for the ZATA’s lab operations. The location has excellent access to Downtown Worcester and to all of New England via I-290, I-190, and the MassPike.

January 2017

R&D team of ZATA published the manuscript describing ZATA’s novel self-neutralizing oligonucleotides with enhance cellular uptake.

https://www.ncbi.nlm.nih.gov/pubmed/28074950

For more information about published compounds as well as viewing earlier patent application: WO/2016/081600 International application No.: PCT/US2015/061343

November 2-3, 2016

President of ZATA participated NIH sponsored Life Science Summit in New-York City where he presented ZATA blood sterilization closed systems and explored potential collaboration opportunities (http://lifesciencessummit.org/).

June 2016

Dr. Ivan B. Yanachkov joined ZATA as VP of Medical Chemistry. Before that Dr. Yanachkov held the position of VP at GLSynthesis, Inc. (Worcester, MA). His extensive experience in the design, synthesis, and testing of large numbers of drug candidates significantly strengthens ZATA’s interdisciplinary team. ZATA welcomes Dr. Yanachkov on board.

May 31, 2016

Canadian Patent Application No.: 2930562 Based on International Application No.: PCT/US2014/065367 Entitled: “AZIRIDINYL CONTAINING COMPOUNDS AND METHODS OF INACTIVATING NUCLEIC ACID MOLECULES USING THE SAME” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.

May 13, 2016

U.S. National Phase Application No.: 15/036,675 with title: “Aziridinyl Containing Compounds And Methods Of Inactivating Nucleic Acid Molecules Using Same” was filed by Pepper Hamilton LLP (Boston, MA) on behalf of ZATA.